How to Get Wegovy in Michigan: Prescriptions, Telehealth, and Pharmacies

What Is Wegovy and Why Does It Require a Prescription?

Wegovy is a brand-name, once-weekly subcutaneous injection of semaglutide 2.4 mg. The FDA granted it approval for chronic weight management in June 2021, specifically for adults with a BMI of 30 or higher, or a BMI of 27 or higher accompanied by at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. Adolescents aged 12 and older with an initial BMI at or above the 95th percentile for age and sex are also eligible.

How Wegovy Works

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the GLP-1 hormone, slowing gastric emptying, reducing appetite signals in the hypothalamus, and increasing satiety after meals. A 2021 mechanistic review published by the NIH described GLP-1 receptor agonists as acting on both peripheral and central pathways to reduce caloric intake.

Clinical Efficacy: The STEP-1 Trial

The key STEP-1 trial enrolled 1,961 adults with obesity or overweight plus at least one comorbidity. At 68 weeks, participants receiving semaglutide 2.4 mg lost a mean of 14.9% of body weight compared to 2.4% in the placebo group (P<0.001). Wilding JPH et al., NEJM 2021. That is roughly a 12.5 percentage-point difference. Approximately 86% of participants on semaglutide achieved at least 5% weight loss, versus 32% on placebo.

Cardiovascular Benefit: SELECT Trial Data

Wegovy carries an FDA-approved cardiovascular indication as well. The SELECT trial (N=17,604) demonstrated a 20% relative risk reduction in major adverse cardiovascular events among adults with pre-existing cardiovascular disease and overweight or obesity, without type 2 diabetes. SELECT results are summarized in the updated FDA prescribing information. Michigan clinicians treating patients with both obesity and cardiovascular disease may find this indication clinically relevant for insurance coverage arguments.

Because Wegovy affects appetite regulation, metabolic function, and cardiovascular physiology, it is a Schedule-uncontrolled but prescription-only drug. No pharmacy in Michigan may dispense it without a valid prescription from a licensed prescriber.

Who Can Prescribe Wegovy in Michigan?

Michigan law allows several categories of clinicians to prescribe Wegovy, provided they hold a valid Michigan license and operate within their scope of practice.

Licensed Prescribers in Michigan

The following professionals may prescribe Wegovy to Michigan patients:

• Medical Doctors (MDs) and Doctors of Osteopathic Medicine (DOs) licensed under the Michigan Public Health Code, Act 368 of 1978.
• Nurse Practitioners (NPs) holding a Michigan license and a specific prescriptive authority designation. Michigan NPs practice under a collaborative practice agreement with a physician in most ambulatory settings, though recent amendments have expanded independent prescribing in certain circumstances.
• Physician Assistants (PAs) with a Michigan license. PAs in Michigan prescribe under a supervising physician's delegation.

Michigan's prescriptive authority framework for NPs and PAs is governed by the Michigan Board of Nursing and the Michigan Board of Medicine, respectively, under Public Health Code 333.

Any of these providers can write a Wegovy prescription at an in-person visit or via a Michigan-compliant telehealth encounter. The prescription itself carries the same legal weight regardless of the modality used to conduct the visit.

Specialist vs. Primary Care

No Michigan law requires an endocrinologist or obesity medicine specialist to prescribe Wegovy. A primary care physician, internal medicine physician, or even a psychiatrist operating within scope may prescribe it. Obesity medicine board-certified clinicians (American Board of Obesity Medicine, ABOM) often have the most structured dosing and monitoring protocols, but board certification is not a prerequisite.

How to Get a Wegovy Prescription in Michigan: Step by Step

Getting a Wegovy prescription in Michigan involves five sequential steps. Each has a typical time range.

Step 1: Determine Eligibility (Day 0 to Day 3)

Before any consultation, confirm your approximate BMI. Online BMI calculators can provide a rough estimate. A BMI of 30 or above, or 27 or above with a documented comorbidity, places you within the FDA-labeled indication. The CDC's BMI calculator is publicly available and uses standard NIH height-weight inputs.

Documented comorbidities that qualify at BMI ≥27 include:

• Type 2 diabetes mellitus
• Hypertension (diagnosed, not just elevated readings)
• Dyslipidemia (e.g., LDL above goal on repeat labs)
• Obstructive sleep apnea
• Cardiovascular disease

Step 2: Order Baseline Labs (Day 1 to Day 7)

Most Michigan prescribers require baseline labs before initiating Wegovy. Common panels include:

• Fasting glucose and HbA1c
• Comprehensive metabolic panel (CMP) to assess renal and hepatic function
• Fasting lipid panel
• Thyroid-stimulating hormone (TSH), because semaglutide carries an FDA black-box warning for medullary thyroid carcinoma (MTC) risk in patients with personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2)
• Complete blood count (CBC) in some practices

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends baseline cardiometabolic labs prior to initiating GLP-1 receptor agonists. Lab results from any Michigan-licensed clinical laboratory are acceptable. Results from national chains such as Quest Diagnostics or LabCorp are standard.

Step 3: Complete the Clinical Consultation (Day 3 to Day 14)

The consultation may be in-person at a Michigan clinic or via a Michigan-authorized telehealth platform (see the dedicated telehealth section below). During this visit the prescriber will:

1. Review your BMI and comorbidity documentation.
2. Evaluate contraindications: personal or family history of MTC, MEN2, or prior pancreatitis.
3. Assess concurrent medications for interactions (e.g., oral contraceptives may require backup contraception because Wegovy slows gastric absorption).
4. Document the clinical rationale required for prior authorization if you are using insurance.
5. Provide injection training or direct you to Novo Nordisk's training resources.

Step 4: Submit the Prescription and Handle Prior Authorization (Day 7 to Day 21)

Once the prescriber sends the prescription electronically to your chosen Michigan pharmacy, the pharmacy checks your insurance. If prior authorization (PA) is required, the prescriber's office submits a PA packet typically including:

• Documented BMI and comorbidities
• Evidence of prior weight loss attempts (diet, exercise, behavioral programs)
• Baseline lab results
• Letter of medical necessity

CMS guidance on prior authorization processes for prescription drugs is publicly accessible and outlines the documentation standards that commercial and Medicaid plans typically mirror.

Michigan Medicaid (Michigan Health Plan, MHP) covers Wegovy for chronic weight management with PA. Commercial insurers in Michigan vary: some Blue Cross Blue Shield of Michigan plans cover Wegovy with step therapy requirements (documented failure of orlistat or phentermine/topiramate first), while others require only BMI documentation and a comorbidity. Confirm your specific plan's formulary before your consultation.

Step 5: Pick Up or Receive Your Medication (Day 14 to Day 21)

After PA approval, the pharmacy dispenses Wegovy. Major Michigan pharmacy chains stocking Wegovy include CVS, Walgreens, Meijer, Rite Aid, and Kroger. Specialty pharmacy fulfillment is also an option if your local pharmacy shows out-of-stock status. Novo Nordisk's patient support line (1-833-NOVO-411) can help locate in-stock Michigan dispensaries.

Telehealth Options for Wegovy in Michigan

Michigan permits telehealth prescribing for Wegovy. The Michigan Department of Licensing and Regulatory Affairs (LARA) recognizes synchronous audio-visual telehealth encounters as equivalent to in-person visits for prescribing purposes, provided the prescriber holds a valid Michigan license or a Michigan telehealth registration if licensed in another state.

What Michigan Telehealth Platforms Offer

Telehealth platforms operating in Michigan and focused on metabolic or weight management conditions typically provide:

• An asynchronous intake questionnaire covering medical history, current medications, and contraindications
• Synchronous video consultation with a licensed Michigan prescriber (MD, DO, NP, or PA)
• Electronic prescription transmission to a Michigan pharmacy of your choice
• Ongoing monthly or quarterly check-ins for dose escalation management
• Lab coordination with national phlebotomy networks

The HealthRX clinical team uses a structured intake protocol for Michigan patients seeking semaglutide 2.4 mg: intake questionnaire reviewed within 24 hours, lab requisition issued within 48 hours if needed, physician review of results and video consultation scheduled within 72 hours of lab return, and prescription transmitted same day as the consultation. This four-step cadence brings most Michigan patients from first contact to dispensed medication in 10 to 14 business days.

Prescribing Rules Telehealth Providers Must Follow

Michigan telehealth prescribers must still meet all standard-of-care requirements. A prescriber cannot issue a Wegovy prescription based solely on an intake form without a documented clinical encounter. The Ryan Haight Online Pharmacy Consumer Protection Act governs online prescribing of certain drugs nationally, though Wegovy is not a controlled substance and therefore faces fewer federal restrictions. The controlling limitation is Michigan's standard-of-care standard: the telehealth encounter must be sufficient to establish a valid patient-prescriber relationship.

Michigan's telehealth policy framework is described under Executive Order 2020-30 and subsequent codification in MCL 333.16285.

Wegovy at Michigan Pharmacies: Retail, Mail-Order, and 503A Compounding

Retail Pharmacies

Wegovy's supply constraints eased significantly through 2024 and into 2025. FDA's drug shortage database removed semaglutide 2.4 mg from active shortage status in early 2025. The FDA's drug shortage database is updated weekly. Most high-volume Michigan retail pharmacies now carry Wegovy on their standard formulary. Call ahead to confirm stock for your specific dose (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, or 2.4 mg pens).

Mail-Order and Specialty Pharmacy

Michigan patients enrolled in Michigan Health Plan or a commercial plan with a mandatory mail-order benefit may receive Wegovy through mail-order specialty pharmacies. Cold-chain shipping maintains the medication at 36 to 46 degrees Fahrenheit. You do not need to pick it up at a retail location.

503A Compounding Pharmacies in Michigan

Michigan-licensed 503A pharmacies are state-licensed compounding pharmacies that compound drugs for individual patients based on a valid prescription. During the FDA-declared shortage period, 503A pharmacies could legally compound semaglutide. With semaglutide 2.4 mg removed from the FDA shortage list, 503A compounders face significant legal restrictions on compounding copies of FDA-approved drugs. The FDA has signaled enforcement action against 503A pharmacies continuing to compound semaglutide after shortage resolution.

If a Michigan 503A pharmacy is offering "compounded semaglutide 2.4 mg" as of mid-2025, confirm the current legal status directly with the prescriber and the pharmacy's compliance officer. Compounded versions are not FDA-approved, do not carry the clinical trial evidence base of branded Wegovy, and may carry different inactive ingredient profiles.

Prior Authorization Documentation in Michigan: What to Prepare

Prior authorization denials are among the most common reasons Michigan patients experience delays. Preparing the documentation in advance reduces the PA timeline from weeks to days.

Required Documentation

Most Michigan commercial insurers and Michigan Medicaid require:

• A letter of medical necessity from the prescriber, signed and dated within 90 days of the PA submission
• BMI documentation from an in-office visit or telehealth encounter (self-reported BMI is generally not accepted)
• Comorbidity diagnosis codes (ICD-10): E11 for type 2 diabetes, I10 for hypertension, E78.5 for hyperlipidemia, G47.33 for obstructive sleep apnea
• Evidence of prior weight management intervention: at minimum a documented conversation about diet and exercise in the medical record, or enrollment in a structured program such as the CDC National Diabetes Prevention Program
• Lab results supporting metabolic status

The American Association of Clinical Endocrinology (AACE) 2022 clinical practice guidelines on obesity recommend documenting weight history, previous pharmacotherapy, and comorbid conditions as the minimum data set for any obesity medication PA submission.

Step Therapy Requirements

Some Blue Cross Blue Shield of Michigan plans require documented trial and inadequate response to at least one first-line obesity agent before approving Wegovy. First-line agents commonly specified include orlistat (Xenical, 120 mg three times daily with meals) or phentermine-topiramate extended release (Qsymia). If you have previously tried either of these medications without achieving adequate weight loss, retain those medical records. They can cut weeks off the PA process.

Appeals

If PA is denied, Michigan law gives patients and prescribers the right to appeal. An expedited appeal must receive a decision within 72 hours for urgent cases. A standard appeal is resolved within 30 days. The prescriber's office typically manages the appeal; your role is to provide any additional documentation they request promptly.

Contraindications and Safety Considerations

Prescribers in Michigan, whether in person or via telehealth, will screen for the following contraindications before prescribing Wegovy.

Absolute Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia type 2 (MEN2)
• Known hypersensitivity to semaglutide or any Wegovy excipient
• Pregnancy (Wegovy carries an FDA Pregnancy Category warning; adequate contraception is required)

Relative Contraindications and Precautions

• History of pancreatitis: the prescriber must weigh risk carefully; semaglutide has been associated with increased pancreatic enzyme levels in some patients
• Diabetic retinopathy: rapid glucose reduction may temporarily worsen retinopathy in patients with pre-existing disease, per the SUSTAIN-6 trial data
• Severe renal impairment: dose adjustment is not specifically required per FDA labeling, but monitoring is recommended
• Concomitant use of other GLP-1 receptor agonists or insulin: combination carries additive hypoglycemia risk

The FDA prescribing label includes a complete contraindication and precaution table.

The most common adverse effects reported in STEP-1 were gastrointestinal: nausea (44% on semaglutide vs. 16% placebo), diarrhea (30% vs. 16%), and vomiting (24% vs. 6%). These effects are most pronounced during the dose escalation phase and tend to diminish after reaching maintenance dose.

Dose Escalation Schedule

The FDA-approved dose escalation for Wegovy is fixed regardless of where you receive care in Michigan.

| Weeks | Dose | |-------|------| | 1 to 4 | 0.25 mg once weekly | | 5 to 8 | 0.5 mg once weekly | | 9 to 12 | 1.0 mg once weekly | | 13 to 16 | 1.7 mg once weekly | | 17 onward | 2.4 mg once weekly (maintenance) |

If gastrointestinal side effects are intolerable at a given dose, the prescriber may delay escalation by four additional weeks at the current dose. This flexible escalation approach is consistent with the ADA Standards of Medical Care in Diabetes 2024, which endorse GLP-1 RA dose titration based on tolerability.

Patients who do not achieve at least 5% weight loss after 16 weeks at the 2.4 mg maintenance dose should discuss with their prescriber whether to continue. The STEP-1 protocol used 68 weeks as the primary endpoint; real-world discontinuation decisions are individualized.

Cost and Savings Programs in Michigan

Wegovy's list price is approximately $1,349 per month for four pens (four weeks of therapy) as of early 2025. Out-of-pocket cost varies significantly based on insurance coverage.

• Novo Nordisk's WeightWatchers Savings Offer: eligible commercially insured Michigan patients may pay as little as $25 per month. This offer is not valid for Michigan Medicaid or Medicare Part D beneficiaries.
• Michigan Medicaid: covered with PA, as noted above. No copay for most Michigan Medicaid enrollees once PA is approved.
• Medicare Part D: as of January 2025, Medicare does not cover Wegovy for weight management alone. Michigan Medicare beneficiaries with an approved cardiovascular indication (SELECT trial criteria) may have access through some Part D plans covering the cardiovascular indication.

Novo Nordisk's patient assistance program (NovoCare) provides Wegovy at no cost to patients meeting low-income criteria. Michigan residents can apply at the NovoCare portal with proof of income. Income threshold is typically at or below 400% of the federal poverty level.

Transferring a Wegovy Prescription to Michigan

Michigan residents who received a Wegovy prescription in another state and are relocating or snowbirding can transfer their prescription to a Michigan pharmacy. The process is straightforward.

A retail pharmacy-to-pharmacy transfer is permitted for non-controlled substances under Michigan pharmacy law. Contact your new Michigan pharmacy with your current pharmacy's name, address, phone number, and your prescription number. The Michigan pharmacist will call the originating pharmacy to complete the transfer.

If you are switching from an out-of-state telehealth provider to a Michigan telehealth provider, the new provider must conduct an independent clinical assessment. They cannot simply continue a prescription initiated by a provider in another state without establishing their own patient-prescriber relationship under Michigan standards.

Note that prescription transfers do not transfer prior authorization. If your Michigan insurer is different from your prior-state insurer, you will need a new PA submission through your Michigan plan.